Last updated: February 21, 2026
What is Citanest and What Are Its Current Clinical Trial Statuses?
Citanest (generic: prilocaine with epinephrine) is a local anesthetic used in dental, minor surgical, and diagnostic procedures. It provides local anesthesia with a preference for procedures requiring extended numbing duration.
Clinical Trial Landscape
As of 2023, Citanest's development pathway includes several investigations aimed at expanding its safety profile, testing new formulations, and exploring additional indications beyond dental anesthesia.
-
Ongoing Trials:
- Formulation Optimization: Several studies focus on delivering prilocaine with epinephrine in sustained-release formats to prolong anesthesia.
- Safety Assessments: Trials evaluating cardiovascular safety, especially in patients with comorbidities.
- New Indication: Pilot studies assessing efficacy in minor dermatological procedures.
-
Regulatory Status:
- Citanest, already approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulators for specific uses, is considered for new formulations pending trial outcomes and regulatory submissions.
-
Future Trials:
- Phase IV post-marketing studies are expected to monitor long-term safety and effectiveness in broader populations.
How Does the Market for Citanest Current Shape Up?
Market Size and Share
The global local anesthetic market was valued at approximately USD 1.7 billion in 2022, with dental applications comprising roughly 40% of sales.[1] Citanest holds an estimated 8-12% share within dental anesthetics, competing mainly with lidocaine, articaine, and mepivacaine.
Competitive Landscape
Key competitors include:
- Lidocaine (market leader)
- Articaine
- Mepivacaine
- Bupivacaine
Citanest differentiates through its longer duration and reduced systemic toxicity risk, especially suited for patients needing longer procedures.
Pricing Dynamics
In the U.S., the average wholesale price (AWP) for Citanest per cartridge ranges from USD 7-10, depending on the concentration and formulation. This contrasts with lidocaine, which averages USD 4-6.
Regulatory Influence and Market Access
Regulatory approvals in China, Japan, and emerging markets continue to expand access, influencing sales growth. Licensing arrangements and patent protections extend through at least 2030 in key markets.
What Are the Market Growth Drivers and Risks?
Drivers
- Rising prevalence of dental conditions requiring local anesthesia.
- Expansion into new indications and formulations.
- Increasing adoption in emerging markets due to healthcare infrastructure improvements.
- Greater awareness of safety profiles compared to older anesthetics.
Risks
- Patent expirations of key formulations scheduled by 2025-2028.
- Competition from cheaper generics and alternative formulations.
- Regulatory hurdles for new formulations, especially sustained-release systems.
- Market saturation in mature regions.
What Are the Future Market Projections?
Revenue Forecasts
The global local anesthetic market is projected to grow at a compound annual growth rate (CAGR) of approximately 4% between 2023 and 2028.[2] Citanest-specific sales are expected to increase by about 5-6% annually, driven by expansion into new markets and formulations.
| Year |
Estimated Market Size |
Citanest Revenue Estimate |
| 2023 |
USD 1.7 billion |
USD 180 million |
| 2025 |
USD 2.0 billion |
USD 220 million |
| 2028 |
USD 2.4 billion |
USD 280 million |
Innovation and Product Pipeline Impact
Development of sustained-release formulations could add USD 50-100 million annually by 2027, contingent on successful clinical trials and regulatory approval.
Key Takeaways
- Citanest operates in a mature market with stable demand primarily driven by dental applications.
- Ongoing clinical trials aim to improve formulations and broaden indications.
- Market share remains steady, with growth potential in emerging markets and new formulations.
- Competitive pressure from generics and alternative anesthetics influences pricing and margins.
- Future revenues could benefit significantly from sustained-release products and new regional approvals.
FAQs
Q1: What clinical indications are most common for Citanest?
Dental procedures, especially root canals, extractions, and minor surgeries.
Q2: Are there any recent regulatory changes affecting Citanest?
No recent changes; it remains approved in major markets with ongoing studies for new formulations.
Q3: How does Citanest compare to lidocaine in efficacy?
Citanest provides longer duration with similar onset, but is more expensive.
Q4: What are the main challenges for Citanest’s market expansion?
Patent expirations, price competition, and gaining approvals for new formulations.
Q5: What is the expected impact of sustained-release formulations?
Potential to increase sales by offering longer-lasting anesthesia, meeting unmet clinical needs.
References
- Markets and Markets. (2022). Local Anesthetics Market Forecast.
- Grand View Research. (2023). Dental Local Anesthetics Market Size and Trends.
